Recombinant Human EGFRVIII Protein, Active

Product Overview Description Recombinant Human EGFRVIII Protein is expressed from HEK293 with His tag and Avi tag at the N-Terminus.It contains Leu25-Ser378. Purity > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC Accession NP_001333870.1 Target Symbol EGFRVIII Synonyms ErbB; EC 2.7.10; EC 2.7.10.1; EGFR; mENA; LEGFR; ERBB; ERBB1; HER1; PIG61; NISBD2 Species Human Expression System HEK293 Tag C-His-Avi Expression Range Leu25-Ser378 Mol. Weight The protein has a predicted MW of 41.6 kDa. Due to glycosylation, the protein migrates to 68-80 kDa based on Tris-Bis PAGE result. Form Lyophilized Formulation Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. Endotoxin Less than 1EU per ug by the LAL method. Activity Immobilized Human EGFRVIII, His Tag at 1ug/ml (100ul/Well) on the plate. Dose response curve for Anti-EGFRVIII Antibody, hFc Tag with the EC50 of 9.6ng/ml determined by ELISA. Contact us for detailed testing images. Storage Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Shipping Shipped at ambient temperature. Gene Background The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene amplification frequently contain EGFR gene rearrangements, with the most common extracellular domain mutation being EGFRvIII. This mutation leads to a deletion of exons 2-7 of the EGFR gene and renders the mutant receptor incapable of binding any known ligand.